SSY Group Limited

2005

KYG8406X1034

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 11:58:23 2024-04-24 pm EDT			5-day change	1st Jan Change
4.76 ^HKD	0.00%		+1.71%	-3.64%

Apr. 23	SSY Group Get Production, Registration Approval for Pneumonia Drug from Chinese Regulator	MT
Apr. 16	SSY Group Logs Nearly 15% Boost in Q1 Profit	MT

SSY Group Considers A Possible Spin-Off of Jiangsu Best New Medical Material

October 18, 2021 at 04:42 am EDT

SSY Group Limited (SEHK:2005) considering a possible spin-off and separate listing of Jiangsu Best New Medical Material Co., Ltd. The company is considering spin-off of Jiangsu Best New Medical on a stock exchange in Mainland China.

Latest news about SSY Group Limited

SSY Group Get Production, Registration Approval for Pneumonia Drug from Chinese Regulator	Apr. 23	MT
SSY Group Logs Nearly 15% Boost in Q1 Profit	Apr. 16	MT
SSY Group Provides Updates on Respiratory Infection, Hypertension Drugs	Apr. 08	MT
SSY Group Limited Announces Update on Product Development	Apr. 08	CI
SSY Group's Two Drugs Get China's NMPA's Nod for Production and Registration	Apr. 03	MT
SSY Group Limited Provides Update on Product Development	Apr. 03	CI
SSY Group's Profit Jumps 17% in 2023	Mar. 27	MT
SSY Group Limited Announces Final Dividend for the Year Ended 31 December 2023, Payable on 04 June 2024	Mar. 27	CI
SSY Group Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
SSY Group Obtains Drug Administration Approval for Diabetes Drug	Mar. 25	MT
SSY Gets Registration Approval for Parkinson’s Drug from Chinese Regulator	Mar. 20	MT
SSY Group Limited Announces Update on Product Development	Mar. 20	CI
SSY Group Gets Bulk Drug Approval from Chinese Authorities	Mar. 01	MT
SSY Group’s Angina Drug Gets Production, Registration Go-Ahead from Chinese Regulator	Mar. 01	MT
SSY Group Limited Obtains Approval for Drug Production and Registration for Nicorandil for Injection from the National Medical Products Administration of China	Feb. 29	CI
SSY Group Limited Announces its Norepinephrine Bitartrate Obtains the Approval for Registration from the National Medical Products Administration of China to Become a Bulk Drug for the Preparations on the Market	Feb. 29	CI
SSY Group’s Blood Sugar Level Drug Passes Chinese Regulator’s Quality and Efficacy Consistency Evaluation	Feb. 27	MT
SSY Group Limited Receives Approval for Gliclazide Tablet	Feb. 27	CI
China Gives Drug Production Nod to SSY's Sodium Bicarbonate Ringer's Injection	Feb. 23	MT
SSY Group Limited Provides Update on Product Development	Feb. 22	CI
SSY Group’s Anesthetic Drug Granted Production, Registration Approval in China	Feb. 19	MT
SSY Group Limited Obtains the Approval for Drug Production and Registration for Propofol Medium and Long Chain Fat Emulsion Injection from the National Medical Products Administration of China	Feb. 18	CI
SSY Group Gets Bulk Drug Approval in China	Jan. 31	MT
SSY Group Limited Announces Update on Product Development	Jan. 31	CI
SSY Obtains Chinese Bulk Drug Registration Nod for Lidocaine Hydrochloride	Jan. 23	MT

Chart SSY Group Limited

Duration

Period

More charts

Company Profile

SSY Group Ltd, formerly known as Lijun International Pharmaceutical Holding Co Ltd, is an investment holding company principally engaged in the research, development, manufacture and sale of pharmaceutical products. The Companyâs main products include finished medicines of mainly intravenous infusion solution to hospitals and distributors, bulk pharmaceuticals and medical materials. The Companyâs products mainly include non-PVC (Polyvinyl chloride) soft bag infusion solution, PP (Polypropylene) plastic bottle infusion solution and Glass bottle infusion solution. The Companyâs products also include Hydrochloride Betahistine, Hydrochloride Ambroxol and Doxofylline as well as bulk pharmaceuticals including caffeine, theophylline, aminophylline, metronidazole and nifedipine.

Sector

Pharmaceuticals

Calendar

2024-05-20 - Final dividend

More about the company

Income Statement Evolution

More financial data

Ratings for SSY Group Limited

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.76 HKD

Average target price

6.227 HKD

Spread / Average Target

+30.81%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SSY GROUP LIMITED	-3.64%	1.8B
ELI LILLY AND COMPANY	+25.61%	660B
NOVO NORDISK A/S	+25.87%	562B
JOHNSON & JOHNSON	-5.24%	358B
MERCK & CO., INC.	+16.49%	322B
ABBVIE INC.	+8.28%	297B
ASTRAZENECA PLC	+7.09%	219B
ROCHE HOLDING AG	-9.12%	196B
NOVARTIS AG	+5.01%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals

SSY Group Limited

Equities

2005

KYG8406X1034

Pharmaceuticals

SSY Group Considers A Possible Spin-Off of Jiangsu Best New Medical Material

Latest news about SSY Group Limited

Chart SSY Group Limited

Company Profile

Income Statement Evolution

Ratings for SSY Group Limited

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals